Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675084 | 0.95 | PPARA (0.60) | PPARAKAT8 | |
| SCHEMBL5192971 | 0.90 | GAA (0.49) | PPARA | |
| SCHEMBL5676633 | 0.88 | KAT8 (0.54) | PPARAKAT8HPGD | |
| SCHEMBL5681042 | 0.83 | TRPA1 (0.52) | — | |
| SCHEMBL3661443 | 0.80 | TUBB4A (0.69) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL237888 | 0.80 | PSMB5 (0.50) | PPARAHPGD | |
| SCHEMBL2873181 | 0.78 | TTR (0.64) | — | |
| SCHEMBL5678474 | 0.78 | TYR (0.42) | PPARAKAT8 | |
| SCHEMBL4372921 | 0.77 | PPARA (0.52) | PPARAKAT8NPC1HPGDMAPK1 | |
| SCHEMBL4374119 | 0.77 | PPARA (0.52) | PPARAKAT8NPC1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620447-B1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEM PATENTS INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | PPARA 3398/4885KAT8 2412/4885NPC1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.